Previous Close | 2.6600 |
Open | 2.7900 |
Bid | 2.6100 |
Ask | 3.1500 |
Strike | 15.50 |
Expire Date | 2024-07-12 |
Day's Range | 2.7900 - 2.7900 |
Contract Range | N/A |
Volume | |
Open Interest | 4 |
The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 61,760 shares of Novavax Inc. Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission is in line with guidance from EMA and the World Health Organization to target the JN.1 lineage this fall.1,2